Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $724.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 43.41% year-over-year to $724.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 17.73% YoY) and the FY2025 annual result came in at $751.6 million, up 36.49% from the prior year.
• Liabilities and Shareholders Equity fell to $724.0 million in Q1 2026, from $751.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $751.6 million in Q4 2025 to a low of $451.8 million in Q1 2023.
• A 5-year average of $541.3 million and a median of $523.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 13.34% — and 2026, when it soared 43.41%.
• Tracing AUPH's Liabilities and Shareholders Equity over 5 years: stood at $470.9 million in 2022, then climbed by 16.4% to $548.1 million in 2023, then advanced by 0.47% to $550.6 million in 2024, then jumped by 36.49% to $751.6 million in 2025, then retreated by 3.67% to $724.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $724.0 million (Q1 2026), $751.6 million (Q4 2025), and $527.5 million (Q3 2025), per Business Quant data.